|
1
|
Cancer stem cell definitions and terminology: the devil is in the details.
|
Nat Rev Cancer
|
2012
|
2.76
|
|
2
|
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.
|
Blood
|
2006
|
1.85
|
|
3
|
How I manage priapism in chronic myeloid leukaemia patients.
|
Br J Haematol
|
2012
|
1.70
|
|
4
|
Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells.
|
Lab Chip
|
2009
|
1.61
|
|
5
|
Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.
|
Blood
|
2011
|
1.46
|
|
6
|
Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
|
Cancer Res
|
2008
|
1.30
|
|
7
|
Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.
|
Clin Cancer Res
|
2006
|
1.29
|
|
8
|
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
|
Blood
|
2013
|
1.16
|
|
9
|
The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.
|
Stem Cells
|
2014
|
1.13
|
|
10
|
Targeting hedgehog in hematologic malignancy.
|
Blood
|
2012
|
1.05
|
|
11
|
BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.
|
Blood
|
2009
|
1.02
|
|
12
|
Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications.
|
Cancer Res
|
2013
|
0.98
|
|
13
|
Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation.
|
Blood
|
2013
|
0.98
|
|
14
|
DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.
|
Genome Biol
|
2014
|
0.95
|
|
15
|
Targeting self-renewal pathways in myeloid malignancies.
|
Cell Commun Signal
|
2013
|
0.87
|
|
16
|
Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia.
|
Blood
|
2008
|
0.86
|
|
17
|
Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation.
|
Leuk Lymphoma
|
2012
|
0.83
|
|
18
|
Cell chip array for microfluidic proteomics enabling rapid in situ assessment of intracellular protein phosphorylation.
|
Biomicrofluidics
|
2011
|
0.81
|
|
19
|
Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients.
|
Proteomics
|
2013
|
0.81
|
|
20
|
Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection.
|
Br J Haematol
|
2005
|
0.79
|
|
21
|
Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.
|
Cancer
|
2005
|
0.79
|
|
22
|
Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform.
|
Integr Biol (Camb)
|
2012
|
0.78
|
|
23
|
Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.
|
Blood
|
2012
|
0.78
|
|
24
|
Novel drug therapies in myeloid leukemia.
|
Pharm Pat Anal
|
2015
|
0.77
|
|
25
|
Targeting chronic myeloid leukemia stem cells.
|
Curr Hematol Malig Rep
|
2013
|
0.76
|